PANOVA-3: A phase III study of TTFields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC)

被引：0
|
作者：
Weinberg, Uri [1 ]
Farber, Ori [2 ]
Giladi, Moshe [2 ]
Bomzon, Zeev [2 ]
Lavy-Shahaf, Gitit [2 ]
Kirson, Eilon D. [2 ]
机构：
[1] Novocure GmbH, Root, Switzerland
[2] Novocure, Haifa, Israel
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT157
引用
收藏
页数：2
相关论文
共 50 条
  • [21] PANOVA: A pilot study of TTFields concomitant with gemcitabine for front-line therapy in patients with advanced pancreatic adenocarcinoma.
    Rivera, Fernando
    Gallego, Javier
    Guillen, Carmen
    Benavides, Manuel
    Lopez-Martin, Jose A.
    Betticher, Daniel C.
    Kueng, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [22] Gemcitabine plus Nab-Paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC)
    Olowokure, Olugbenga
    Torregroza-Sanchez, Maria Patricia
    Bedoya-Apraez, Ivan Dario
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2013, 4 (02) : E16 - E18
  • [23] Third -line re -treatment of advanced pancreatic adenocarcinoma with gemcitabine and nab-paclitaxel
    Das, A.
    Dean, A.
    McNulty, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia
    Rogers, Jane E.
    Mizrahi, Jonathan D.
    Shroff, Rachna T.
    Nelson, Douglas A.
    Tu, Janet
    Javle, Milind M.
    Wolff, Robert A.
    Pant, Shubham
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 11 (01) : 55 - 60
  • [25] PANOVA-3: A phase 3 study of tumor-treating fields with gemcitabine and nabpaclitaxel for frontline treatment of locally advanced pancreatic adenocarcinoma
    Picozzi, Vincent J.
    Macarulla, Teresa
    Philip, Agop Philip
    Becerra, Carlos Roberto
    Dragovich, Tomislav
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Shuling Chen
    Jiaxin Li
    Aoran Dong
    Zelong Liu
    Meiyan Zhu
    Meng Jin
    Guangyan Wei
    Shuang Wu
    Yan Wang
    Yong Chen
    Zhenwei Peng
    Journal of Hematology & Oncology, 16
  • [27] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Chen, Shuling
    Li, Jiaxin
    Dong, Aoran
    Liu, Zelong
    Zhu, Meiyan
    Jin, Meng
    Wei, Guangyan
    Wu, Shuang
    Wang, Yan
    Chen, Yong
    Peng, Zhenwei
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [28] Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma
    Nebot-Villacampa, Maria-Jose
    Zafra-Morales, Ricardo
    Alfaro-Olea, Ascension
    Marin-Gorricho, Raquel
    Casajus-Navasal, Andrea
    Uriarte-Pinto, Moises
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (03) : 603 - 611
  • [29] FOLFIRINOX and gemcitabine/nab-paclitaxel efficacy in the treatment of locally advanced unresectable pancreatic adenocarcinoma.
    Bednar, Filip
    Ocuin, Lee Mayer
    Steve, Jennifer
    Zenati, Mazen S.
    Winters, Sharon
    Hogg, Melissa Ellen
    Bahary, Nathan
    Zeh, Herbert J.
    Zureikat, Amer H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [30] A PHASE 1 STUDY OF GEMCITABINE / NAB-PACLITAXEL / S-1 (GAS) COMBINATION NEOADJUVANT CHEMOTHERAPY FOR PATIENTS WITH LOCALLY-ADVANCED PANCREATIC ADENOCARCINOMA
    Kondo, Naru
    Murakami, Yoshiaki
    Uemura, Kenichiro
    Sudo, Takeshi
    Hashimoto, Yasushi
    Nakagawa, Naoya
    Sueda, Taijiro
    GASTROENTEROLOGY, 2017, 152 (05) : S1250 - S1250
12345